OVID News and Press, Ovid Therapeutics Inc. From 03/13/23

2023-03-13 08:20:27 ET Ovid Therapeutics press release ( NASDAQ: OVID ): Q4 GAAP EPS of -$0.16 beats by $0.02 . Cash, cash equivalents and marketable securities as of December 31, 2022 totaled $129.0 million. For further details see: Ovid Therapeutics GA...

OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company’s KCC2 activator portfolio Takeda's guidance on soticlestat remains unchanged; anticipates regulatory...

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a fires...

OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal excitation, including epilepsies Two preclinical seizure models suggest that OV350 mitigates neuronal hyperexcitability by reducing intracellular chloride accumul...

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a panel ...

Recognized epileptologist and medical affairs leader, Manoj Malhotra, M.D., joins as Chief Medical Officer Drug discovery and development scientist and soticlestat co-inventor, Toshiya Nishi, D.V.M., joins as Head of Epilepsy Research NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Ov...

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, dosed healthy volunteers with OV329 in late December 2022, a...

Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs Epilepsy Therapy Screening Program demonstrate that OV329 confers protection from seizure a...

Ovid Therapeutics press release ( NASDAQ: OVID ): Q3 GAAP EPS of -$0.17 beats by $0.04 . Revenue of $11.1K. The company ended Q3 with cash, cash equivalents and marketable securities of $137.9M, which is expected to support the advancement of Ovid's epile...

Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase inhibitor The Company ended Q3 2022 with cash, cash equivalents and marketable securities of $...